Opinion - Coxibs: can this class of drugs survive?
Reza TabrizchiDivision of Basic Medical Sciences, Faculty of Medicine, MemorialUniversity of Newfoundland, St John’s, NL, CanadaThe sudden voluntary withdrawal of Oven Door Lock rofecoxib (Vioxx), a “selective” cyclooxygenase 2 (Cox-2) inhibitor, by Merck & Co on September 30, 2004, as a result of its adverse cardiovascular ef